Fixed drug eruption induced by tipepidine hibenzate

Iwabuchi, Chikako; Kanto, Hiromi; Ohashi, Norio; Itoh, Masatoshi

doi:10.1111/j.1346-8138.2010.00806.x

Cited by 3 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, given that methylphenidate is metabolized by hepatic and peripheral esterases, it probably does not interact with the cytochrome P450 enzyme‐based metabolism of tipepidine . Several studies, however, reported a toxic effect for tipepidine, causing agitation, toxic epidermal necrosis, and fixed drug eruption in pediatric populations . In terms of safety, we identified that tipepidine add‐on to methylphenidate resulted in no major adverse events.…”

Section: Discussionmentioning

confidence: 82%

Efficacy and safety of tipepidine as adjunctive therapy in children with attention‐deficit/hyperactivity disorder: Randomized, double‐blind, placebo‐controlled clinical trial

Dehbozorghi

Bagheri

Moradi

et al. 2019

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Aim: This study evaluated the efficacy and safety of tipepidine as an add-on to methylphenidate in the drug treatment of attention-deficit/hyperactivity disorder (ADHD).Methods: This study was an 8-week, randomized, parallel group, double-blind, placebo-controlled trial recruiting 53 ADHD-diagnosed children. Patients were randomly divided to receive methylphenidate + tipepidine or methylphenidate + placebo for 8 weeks. Participants were assessed using the parent version of ADHD Rating Scale-IV and the Clinical Global Impression scale at baseline, at week 4, and at the end of the trial. Moreover, the safety and tolerability of the treatment strategies were compared.Results: On general linear model repeated measures analysis a significant effect was seen for time × treatment interaction on the total and hyperactivity-impulsivity subscales of the Parent ADHD Rating Scale-IV during the trial period (Greenhouse-Geisser corrected: F = 3.45, d.f. = 1.52, P = 0.049, and F = 5.17, d.f. = 1.52, P = 0.014, respectively). The effect for time × treatment interaction, however, was not significant on Clinical Global Impression-Severity scale (Greenhouse-Geisser corrected: F = 1.79, d.f. = 1.43, P = 0.182). The frequencies of adverse events were similar between the two groups.Conclusion: Eight weeks of treatment with tipepidine, as a supplementary medication, resulted in satisfactory efficacy and safety of the adjuvant therapy in management of patients with ADHD. Rigorous investigations, however, involving larger sample sizes, more extended treatment periods, and dose responses should be considered.Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent psychiatric disorders, affecting 3-7% of school-age children. It is delineated by inattentiveness symptoms, impulsive behavior, and hyperactivity in cases lasting for at least 6 months. 1 ADHD patients may have to deal with many challenges due to their unusual characteristics, which persist into adulthood in approximately 60%-80% of cases. 2 In general, patients with ADHD are susceptible to having slower rates of processing, lower self-esteem, increased risk of motor vehicle accidents, sexual and socially related problems, and psychiatric comorbidity. [3][4][5] Attention-deficit/hyperactivity disorder could occur due to imbalance of catecholamine metabolism in the cerebral cortex, and the impaired dopaminergic and noradrenergic function of several areas such as the prefrontal cortex (PFC). 6 Treatment for ADHD consists of behavioral therapy, drug therapy, or a combination of both; the two latter approaches seem to have the most effect. 7-9 Accordingly, the standard treatment for all groups of ADHD currently is focused on modification of the imbalance, using either stimulants or non-stimulants. Among the studied psychostimulants, methylphenidate (Ritalin) is the most extensively used medication, which leads to higher concentrations of synaptic dopamine by inhibiting the dopamine transporter. 10 Ordinarily, stimulants are safe and extremely effective; nonethele...

show abstract

Section: Discussionmentioning

confidence: 82%

Efficacy and safety of tipepidine as adjunctive therapy in children with attention‐deficit/hyperactivity disorder: Randomized, double‐blind, placebo‐controlled clinical trial

Dehbozorghi

Bagheri

Moradi

et al. 2019

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

show abstract

“…Additional trials are needed to evaluate the efficacy and safety for tipepidine use in adolescent depression. Although tipepidine is widely used, however, there are reports25–27 indicating a possible toxic effect like agitation, fixed drug eruption and toxic epidermal necrolysis also in pediatric populations. So we must pay attention to the mood symptoms, especially irritability and cutis symptoms, because there were patients for whom a feeling of irritation and a cutis symptom appeared in this tipepidine study.…”

mentioning

confidence: 99%

Tipepidine in adolescent patients with depression: a 4 week, open-label, preliminary study

Sasaki¹,

Hashimoto²,

Tachibana³

et al. 2014

NDT

View full text Add to dashboard Cite

Current awareness: Pharmacoepidemiology and drug safety

2010

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Fixed drug eruption induced by tipepidine hibenzate

Cited by 3 publications

References 8 publications

Efficacy and safety of tipepidine as adjunctive therapy in children with attention‐deficit/hyperactivity disorder: Randomized, double‐blind, placebo‐controlled clinical trial

Efficacy and safety of tipepidine as adjunctive therapy in children with attention‐deficit/hyperactivity disorder: Randomized, double‐blind, placebo‐controlled clinical trial

Tipepidine in adolescent patients with depression: a 4 week, open-label, preliminary study

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About